Muscarinic modulation of human electroencephalography (EEG) activity using scopolamine

Phase 4

• Conditions: Major depression; Mental Health - Depression

• Registration Number: ACTRN12622000228785
• Lead Sponsor: The University of Auckland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-12-17
• Study Start: 2022-02-09
• Last Update Posted: 25 April 2022

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Male or female, aged 18 years or above and less than 60.
• In the Investigators’ opinion, is able and willing to comply with all trial requirements.
• Participant is willing and able to give informed consent for participation in the trial.

Exclusion Criteria

• Female participant who is pregnant, lactating or planning pregnancy during the course of the trial.
• Regular use of any medication deemed to be contraindicating as judged by the attending study clinicians.
• Contraindication to the use of scopolamine or glycopyrrolate according to manufacturer guideline
• Significant renal or hepatic impairment.
• Participants with glaucoma
• Cardiovascular conditions including abnormal heart rate and blood pressure checked at screening.
• History of psychiatric illness.
• Any unstable medical or neurologic condition.
• Problematic substance dependence in previous 3 months
• Inability to speak or read English.
• Any other condition judged by the treating clinician as likely to impact on the ability of the participant to complete the trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified